MAP2K7 and cancer: As these therapeutics lose their effectiveness within months, most likely by activation of alternative MEK signalling,39 innovative treatments may require additional direct triggering of alternative tumour-specific cell death pathways.40 Inhibition of IAPs is one promising strategy to activate cell death and is currently under clinical investigation in various cancer types (for review, see Wan et al.41).